A Phase 3 Study Comparing Daratumumab, VELCADE [bortezomib], Lenalidomide, and Dexamethasone [D-VRd] vs VELCADE, Lenalidomide, and Dexamethasone [VRd] in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy. (NCT03710603)
Perseus
This trial is No longer recruiting
Registration number NCT03710603
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 3
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Prof Andrew Spencer
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR